[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623995":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":33,"centralContacts":52,"locations":58,"responsibleParty":83,"collaborators":33,"id":86,"slug":87,"hasResults":88,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":88,"sex":94,"minAge":95,"maxAge":33,"enrollmentInfo":96,"targetDuration":33,"studyType":99,"phases":100,"briefSummary":102,"conditions":103,"keywords":105,"overallStatus":113,"whyStopped":33,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":123},{"fullName":5,"class":6},"Fudan University","OTHER",[8,17,22],{"label":9,"type":10,"description":11,"interventionNames":12},"anti-PD-1 plus anti-CTLA-4","EXPERIMENTAL","Arm A: Nivolumab 240 mg every 2 weeks (6 doses) plus ipilimumab 1 mg\u002Fkg every 3 weeks (4 doses).",[13,14,15,16],"Drug: Nivolumab","Drug: Ipilimumab (1mg\u002Fkg)","Procedure: Radical surgery","Other: Watch & wait",{"label":18,"type":10,"description":19,"interventionNames":20},"anti-PD-1 plus radiotherapy","Arm B: Radiotherapy (5 Gy per fraction, total 4 fractions, delivered every 3 weeks) to the primary lesion plus nivolumab 240 mg every 2 weeks (6 doses).",[13,21,15,16],"Radiation: PULSAR",{"label":23,"type":24,"description":25,"interventionNames":26},"anti-PD-1 monotherapy","ACTIVE_COMPARATOR","Arm C: Nivolumab 240 mg every 2 weeks (6 doses).",[13,15,16],[28,34,38,43,48],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"DRUG","Nivolumab","Nivolumab 240 mg every 2 weeks",[23,9,18],null,{"type":29,"name":35,"description":36,"armGroupLabels":37,"otherNames":33},"Ipilimumab (1mg\u002Fkg)","Ipilimumab 1 mg\u002Fkg every 3 weeks",[9],{"type":39,"name":40,"description":41,"armGroupLabels":42,"otherNames":33},"RADIATION","PULSAR","Irradiation targeted to the primary lesion (5 Gy per fraction, total 4 fractions, delivered every 3 weeks).",[18],{"type":44,"name":45,"description":46,"armGroupLabels":47,"otherNames":33},"PROCEDURE","Radical surgery","Surgical resection will be performed in resectable cases.",[23,9,18],{"type":6,"name":49,"description":50,"armGroupLabels":51,"otherNames":33},"Watch & wait","For patients with low rectal cancer who are unable to preserve the anal sphincter, a watch-and-wait (WW) strategy can be considered if a clinical complete response (CR) is achieved.",[23,9,18],[53],{"name":54,"role":55,"phone":56,"phoneExt":33,"email":57},"Menglong Zhou, MD","CONTACT","86+18121299608","mrzhouml@163.com",[59],{"facility":60,"status":33,"city":61,"state":33,"zip":33,"country":62,"countryCode":63,"cosmosGeoPoint":64,"geoPoint":69,"contacts":70},"Fudan University Shanghai Cancer Center","Shanghai","China","CN",{"type":65,"coordinates":66},"Point",[67,68],121.45806,31.22222,{"lat":68,"lon":67},[71,73,76,78,81],{"name":54,"role":55,"phone":72,"phoneExt":33,"email":57},"86-18121299608",{"name":74,"role":75,"phone":33,"phoneExt":33,"email":33},"Sanjun Cai, MD","PRINCIPAL_INVESTIGATOR",{"name":77,"role":75,"phone":33,"phoneExt":33,"email":33},"Zhen Zhang, MD",{"name":79,"role":80,"phone":33,"phoneExt":33,"email":33},"Fangqi Liu, MD","SUB_INVESTIGATOR",{"name":82,"role":80,"phone":33,"phoneExt":33,"email":33},"Fan Xia, MD",{"type":75,"investigatorFullName":84,"investigatorTitle":85,"investigatorAffiliation":5,"oldNameTitle":33,"oldOrganization":33},"Zhen Zhang","Professor, Chief Physician, Department of Radiation Oncology, Fudan University Shanghai Cancer Center","100623995","phase-2-neoadjuvant-immunotherapy--radiotherapy-in-msi-hdmmr-locally-advanced-colorectal-cancer-100623995",false,"NCT07403877","Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H\u002FdMMR Locally Advanced Colorectal Cancer","A Phase II Randomized Controlled Trial of Neoadjuvant Immunotherapy With or Without Radiotherapy in Locally Advanced Microsatellite Instability-High\u002FMismatch Repair-Deficient Colorectal Cancer","TORCH-OPTIMA","Inclusion Criteria:\n\n1. Histopathologically confirmed primary colorectal adenocarcinoma.\n2. Radiographic assessment showed a stage II-III based on AJCC Stage 8th ed.\n3. At least 18 years old.\n4. MSI-H or dMMR.\n5. The Eastern Cooperative Oncology Group performance status (ECOG PS) score is 0 or 1.\n6. Physical state or organ function can tolerate the planned treatment of the study protocol.\n7. Agreed to sign written informed consent before recruitment.\n\nExclusion Criteria:\n\n1. Previously received any antitumor therapy for the disease under study, including surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc.\n2. Pregnancy or breastfeeding women.\n3. History of other malignancies within 5 years.\n4. Serious medical illness, such as severe mental disorders, cardiac disease, uncontrolled infection, etc.\n5. Immunodeficiency disease or long-term using of immunosuppressive agents.\n6. Allergic to any component of the therapy.\n7. Any other condition or disease that is not suitable to take the therapy included in the protocol.\n8. Concurrent participation in another clinical study, unless participating in an observational (non-interventional) clinical study or in the survival follow-up phase of an interventional study.\n9. Received any investigational drug or device treatment within 4 weeks prior to initial administration of the investigational drug.","ALL","18 Years",{"count":97,"type":98},114,"ESTIMATED","INTERVENTIONAL",[101],"PHASE2","This phase II clinical trial evaluates the efficacy and safety of three neoadjuvant regimens in patients with locally advanced microsatellite instability-high\u002Fmismatch repair-deficient (MSI-H\u002FdMMR) colorectal cancer (CRC): 1) Regimen A: Dual immune checkpoint blockade with nivolumab plus ipilimumab. 2) Regimen B: Nivolumab plus radiotherapy. 3) Regimen C: Nivolumab monotherapy. The primary objectives are to determine whether: 1) Dual immune checkpoint blockade (Regimen A) is superior to nivolumab monotherapy (Regimen C); and 2) Immunotherapy plus radiotherapy (Regimen B) is superior to nivolumab monotherapy (Regimen C). Methods: Participants will be randomized in a 1:1:1 ratio to one of the three arms. For patients with resectable tumors, surgical resection will be performed. In patients with low rectal cancer and poor prospects for sphincter preservation, a watch-and-wait (WW) strategy is an option if a clinical complete response (CR) is achieved following neoadjuvant therapy.",[104],"Colorectal Cancer (MSI-H)",[106,107,108,109,110,111,112],"colorectal cancer","microsatellite instability high","mismatch repair-deficient","neoadjuvant therapy","radiotherapy","immunotherapy","locally advanced","NOT_YET_RECRUITING","2026-02-07",{"date":116,"type":117},"2026-02-11","ACTUAL",{"date":119,"type":98},"2026-02-01",{"date":121,"type":98},"2034-12-31",{"name":5,"class":6},1]